卵巢癌化疗耐药机制研究进展
|
摘要
卵巢癌是妇科恶性肿瘤中导致女性死亡的主要原因。目前,临床用于治疗卵巢癌的主要手段是手术切除并联合以铂类为基础的化疗,化疗耐药是卵巢癌复发和治疗失败的主要因素,导致其5年生存率较低。因此,探索与化疗抵抗有关的细胞及分子生物学机制对卵巢癌的化疗具有重要意义。该文就目前与化疗抵抗有关的因素及其对临床化疗的反应作一综述,以期进一步寻求逆转耐药的思路与方法。
引文
[1]Poveda-Velasco A,Casado-Herraez A,Cervantes-Ruiperez A,et al.Treatment guidelines in ovarian cancer[J].Clin Transl Oncol,2007,9(5):308-16.
[2]Mei L,Chen H,Wei D M,et al.Maintenance chemotherapy for ovarian cancer[J].Cochrane Database Syst Rev,2010,9:CD007414.
[3]Yap T A,Carden C P,Kaye S B.Beyond chemotherapy:targeted therapies in ovarian cancer[J].Nat Rev Cancer,2009,9(3):167-81.
[4]Douglas A L,Faina B,Cindy J Y,et al.Frequent mutation of the PIK3CA gene in ovarian and breast cancer[J].Clin Cancer Res,2005,11(8):2875-8.
[5]Abdul-Ghani R,Serra V,Gyorffy B,et al.The PI3-K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1[J].Oncogene,2006,25(12):1742-52.
[6]Kim S H,Juhnn Y S,Song Y S.AKT involvement in paclitaxel chemoresistance of human ovarian cancer cells[J].Ann N Y Acad Sci,2007,1095(1):82-9.
[7]Lee S,Choi E J,Jin C,et al.Activation of PI3K/Akt pathway by PETN reduction and PI3KCA mRNA amplification contributes to cisplatin resistance in ovarian cancer cell line[J].Gynecol Oncol,2005,97(1):26-34.
[8]Carden C P,Stewart A,Thavasu P,et al.The association of PI3kinase signaling and chemoresistance in advanced ovarian cancer[J].Mol Cancer Ther,2012,11(7):1609-17.
[9]Sourbier C.Ovarian cancer:emerging molecular-targeted therapies[J].Biologics,2012,(6):147-54.
[10]Li G M.Mechanisms and functions of DNA mismatch repair[J].Cell Res,2008,18(1):85-98.
[11]Ding X,Mohd A B,Huang Z,et al.MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition[J].Br J Cancer,2009,101(2):269-77.
[12]Watanabe Y,Ueda H,Etoh T,et al.A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinumbased chemotherapy in epithelial ovarian cancer[J].Anticancer Res,2007,27(3B):1449-52.
[13]孟春风,戴冬秋,郭科军.5-氮杂-2-脱氧胞苷和曲古抑菌素A对卵巢癌顺铂耐药细胞中hMLH1表达及DNA甲基化的影响[J].癌症,2008,27(12):1251-5.
[14]Zeller C,Dai W,Steele N L,et al.Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling[J].Oncogene,2012,31(42):4567-76.
[15]Marcelis C L,van der Putten H W,Tops C,et al.Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation[J].Fam Cancer,200l,1(2):107-9.
[16]Duan Z,Brakora K A,Seiden M V.Inhibition of ABCB1(MDR1)and ABCB4(MDR3)expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells[J].Mol Cancer Ther,2004,3(7):833-8.
[17]Zhang H,Wang J,Cai K,et al.Downregulation of gene MDR1by shRNA to reverse multidrug-resistance of ovarian cancer A2780cells[J].J Can Res Ther,2012,8(2):226-31.
[18]陈燕,赵叶芳,韩萍.卵巢癌组织中P-糖蛋白、肺耐药蛋白的表达变化及意义[J].山东医药,2009,49(26):49-50.
[19]Li Z,Hu S,Wang J,et al.MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells[J].Gynecol Oncol,2010,119(1):125-30.
[20]王劲欧,吕庆杰,曹薇,等.ER和MDM2及ERK1/2信号通路与卵巢癌耐药关系的研究[J].中华肿瘤防治杂志,2008,15(19):1458-62.
[21]Yakirevich E,Sabo E,Naroditsky I,et al.Multidrug resistancerelated phenotype and apoptosis-related protein expression in ovarian serous carcinomas[J].Gynecol Oncol,2006,100(1):152-9.
[22]凌晓光,吴强,薛花,等.抗HER-2抗体诱导人卵巢癌裸小鼠移植瘤细胞凋亡及其对凋亡相关蛋白表达的影响[J].临床与实验病理学杂志,2006,22(2):218-22.
[23]Ryan B M,O’Donovan N,Duffy M J.Survivin:a new target for anti-cancer therapy[J].Cancer Treat Rev,2009,35(7):553-62.
[24]Altieri D C.Survivin and IAP proteins in cell-death mechanisms[J].Biochem J,2010,430(2):199-205.
[25]Vivas-Mejia P E,Rodriguez-Aguayo C,Han H D,et al.Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer[J].Clin Cancer Res,2011,17(11):3716-26.
[26]Xing J,Jia C R,Wang Y,et al.Effect of shRNA targeting survivin on ovarian cancer[J].J Cancer Res Clin Oncol,2012,138(7):1221-9.
[27]杨晓葵,郑芳,卢运萍,等.凋亡相关蛋白的表达及Caspase-3活性改变与人卵巢癌细胞顺铂耐药的关系[J].癌症,2002,21(12):1288-91.
[28]Yang X,Fraser M,Moll U M,et al.Akt-mediated cisplain resistance in ovarian cancer:modulation of p53 action on caspase-dependent mitochondrial death pathway[J].Cancer Res,2006,66(6):3126-36.
[29]刘国美,刘莉霞,郭西雨,等.卵巢癌中Caspase-3的表达及与化疗耐药相关性研究[J].现代生物医学进展,2012,12(1):73-6.
[30]Materna V,Surowiak P,Markwitz E,et al.Expression of factors involved in regulation of DNA mismatch repair and apoptosis pathways in ovarian cancer patients[J].Oncol Rep,2007,17(3):505-16.
[31]Kleinberg L,Dong H P,Holth A,et al.Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian cancer carcinoma[J].Hum Pathol,2009,40(6):795-806.
[2]Mei L,Chen H,Wei D M,et al.Maintenance chemotherapy for ovarian cancer[J].Cochrane Database Syst Rev,2010,9:CD007414.
[3]Yap T A,Carden C P,Kaye S B.Beyond chemotherapy:targeted therapies in ovarian cancer[J].Nat Rev Cancer,2009,9(3):167-81.
[4]Douglas A L,Faina B,Cindy J Y,et al.Frequent mutation of the PIK3CA gene in ovarian and breast cancer[J].Clin Cancer Res,2005,11(8):2875-8.
[5]Abdul-Ghani R,Serra V,Gyorffy B,et al.The PI3-K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1[J].Oncogene,2006,25(12):1742-52.
[6]Kim S H,Juhnn Y S,Song Y S.AKT involvement in paclitaxel chemoresistance of human ovarian cancer cells[J].Ann N Y Acad Sci,2007,1095(1):82-9.
[7]Lee S,Choi E J,Jin C,et al.Activation of PI3K/Akt pathway by PETN reduction and PI3KCA mRNA amplification contributes to cisplatin resistance in ovarian cancer cell line[J].Gynecol Oncol,2005,97(1):26-34.
[8]Carden C P,Stewart A,Thavasu P,et al.The association of PI3kinase signaling and chemoresistance in advanced ovarian cancer[J].Mol Cancer Ther,2012,11(7):1609-17.
[9]Sourbier C.Ovarian cancer:emerging molecular-targeted therapies[J].Biologics,2012,(6):147-54.
[10]Li G M.Mechanisms and functions of DNA mismatch repair[J].Cell Res,2008,18(1):85-98.
[11]Ding X,Mohd A B,Huang Z,et al.MLH1 expression sensitises ovarian cancer cells to cell death mediated by XIAP inhibition[J].Br J Cancer,2009,101(2):269-77.
[12]Watanabe Y,Ueda H,Etoh T,et al.A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinumbased chemotherapy in epithelial ovarian cancer[J].Anticancer Res,2007,27(3B):1449-52.
[13]孟春风,戴冬秋,郭科军.5-氮杂-2-脱氧胞苷和曲古抑菌素A对卵巢癌顺铂耐药细胞中hMLH1表达及DNA甲基化的影响[J].癌症,2008,27(12):1251-5.
[14]Zeller C,Dai W,Steele N L,et al.Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling[J].Oncogene,2012,31(42):4567-76.
[15]Marcelis C L,van der Putten H W,Tops C,et al.Chemotherapy resistant ovarian cancer in carriers of an hMSH2 mutation[J].Fam Cancer,200l,1(2):107-9.
[16]Duan Z,Brakora K A,Seiden M V.Inhibition of ABCB1(MDR1)and ABCB4(MDR3)expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells[J].Mol Cancer Ther,2004,3(7):833-8.
[17]Zhang H,Wang J,Cai K,et al.Downregulation of gene MDR1by shRNA to reverse multidrug-resistance of ovarian cancer A2780cells[J].J Can Res Ther,2012,8(2):226-31.
[18]陈燕,赵叶芳,韩萍.卵巢癌组织中P-糖蛋白、肺耐药蛋白的表达变化及意义[J].山东医药,2009,49(26):49-50.
[19]Li Z,Hu S,Wang J,et al.MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells[J].Gynecol Oncol,2010,119(1):125-30.
[20]王劲欧,吕庆杰,曹薇,等.ER和MDM2及ERK1/2信号通路与卵巢癌耐药关系的研究[J].中华肿瘤防治杂志,2008,15(19):1458-62.
[21]Yakirevich E,Sabo E,Naroditsky I,et al.Multidrug resistancerelated phenotype and apoptosis-related protein expression in ovarian serous carcinomas[J].Gynecol Oncol,2006,100(1):152-9.
[22]凌晓光,吴强,薛花,等.抗HER-2抗体诱导人卵巢癌裸小鼠移植瘤细胞凋亡及其对凋亡相关蛋白表达的影响[J].临床与实验病理学杂志,2006,22(2):218-22.
[23]Ryan B M,O’Donovan N,Duffy M J.Survivin:a new target for anti-cancer therapy[J].Cancer Treat Rev,2009,35(7):553-62.
[24]Altieri D C.Survivin and IAP proteins in cell-death mechanisms[J].Biochem J,2010,430(2):199-205.
[25]Vivas-Mejia P E,Rodriguez-Aguayo C,Han H D,et al.Silencing survivin splice variant 2B leads to antitumor activity in taxane-resistant ovarian cancer[J].Clin Cancer Res,2011,17(11):3716-26.
[26]Xing J,Jia C R,Wang Y,et al.Effect of shRNA targeting survivin on ovarian cancer[J].J Cancer Res Clin Oncol,2012,138(7):1221-9.
[27]杨晓葵,郑芳,卢运萍,等.凋亡相关蛋白的表达及Caspase-3活性改变与人卵巢癌细胞顺铂耐药的关系[J].癌症,2002,21(12):1288-91.
[28]Yang X,Fraser M,Moll U M,et al.Akt-mediated cisplain resistance in ovarian cancer:modulation of p53 action on caspase-dependent mitochondrial death pathway[J].Cancer Res,2006,66(6):3126-36.
[29]刘国美,刘莉霞,郭西雨,等.卵巢癌中Caspase-3的表达及与化疗耐药相关性研究[J].现代生物医学进展,2012,12(1):73-6.
[30]Materna V,Surowiak P,Markwitz E,et al.Expression of factors involved in regulation of DNA mismatch repair and apoptosis pathways in ovarian cancer patients[J].Oncol Rep,2007,17(3):505-16.
[31]Kleinberg L,Dong H P,Holth A,et al.Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian cancer carcinoma[J].Hum Pathol,2009,40(6):795-806.